{
    "organizations": [],
    "uuid": "ff2b13262e5f918221f0952b65e67bfeb7471d7b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-proteon-therapeutics-and-lonza-ext/brief-proteon-therapeutics-and-lonza-extend-manufacturing-agreement-for-commercial-supply-idUSFWN1SF0PL",
    "ord_in_thread": 0,
    "title": "BRIEF-Proteon Therapeutics And Lonza Extend Manufacturing Agreement For Commercial Supply",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Proteon Therapeutics Inc:\n* PROTEON THERAPEUTICS AND LONZA EXTEND MANUFACTURING AGREEMENT FOR COMMERCIAL SUPPLY\n* PROTEON THERAPEUTICS INC - PARTNERS EXTEND EXISTING CONTRACT FOR MANUFACTURE OF VONAPANITASE TO 2029 AS ONGOING PHASE 3 TRIAL NEARS COMPLETION\n* PROTEON THERAPEUTICS - CONTRACT EXTENSION WITH LONZA PHARMA & BIOTECH FOR COMMERCIAL SUPPLY OF INVESTIGATIONAL VONAPANITASEâ€™S API Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T19:25:00.000+03:00",
    "crawled": "2018-05-09T12:33:12.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "proteon",
        "therapeutic",
        "inc",
        "proteon",
        "therapeutic",
        "lonza",
        "extend",
        "manufacturing",
        "agreement",
        "commercial",
        "supply",
        "proteon",
        "therapeutic",
        "inc",
        "partner",
        "extend",
        "existing",
        "contract",
        "manufacture",
        "vonapanitase",
        "ongoing",
        "phase",
        "trial",
        "nears",
        "completion",
        "proteon",
        "therapeutic",
        "contract",
        "extension",
        "lonza",
        "pharma",
        "biotech",
        "commercial",
        "supply",
        "investigational",
        "vonapanitase",
        "api",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}